Boehringer Ingelheim Pharma GmbH & Co KG and Cue Biopharma Inc. have signed a strategic research collaboration and license agreement to develop and commercialize Cue Biopharma’s CUE-501, a differentiated B-cell depletion therapy for autoimmune diseases.
Researchers have developed a new compound that can prevent long COVID symptoms in mice that could lead to a future drug for the debilitating condition in humans. Developed by researchers at the Walter and Eliza Hall Institute of Medical Research (WEHI) in Melbourne, the world-first study found mice treated with the antiviral compound were protected from long-term brain and lung dysfunction, which are key symptoms of long COVID.
Aurigene Oncology Ltd. has patented new proteolysis targeting chimera (PROTACs) compounds comprising a protein cereblon (CRBN)-binding moiety covalently bound to a CREB-binding protein (CREBBP; CBP)-targeting moiety through a linker.
NRG Therapeutics Ltd. has described mitochondrial permeability transition (MPT) inhibitors reported to be useful for the treatment of aging, ischemia-reperfusion injury, inflammation, neurodegeneration and autoimmune, metabolic and renal disorders.
Tribune Therapeutics AB has raised €37 million (US$40 million) in seed and series A funding to advance a portfolio of therapies targeting central drivers of scar tissue formation.
The U.S. FDA rejected, for the second time, Elevar Therapeutics Inc.’s NDA of a novel combination therapy for advanced liver cancer, which comprised Jiangsu Hengrui Pharmaceutical Co. Ltd.’s PD-1 inhibitor camrelizumab and HLB Co. Ltd.’s small-molecule tyrosine kinase inhibitor, rivoceranib.
Hillstar Bio came out of stealth mode, announcing a $67 million series A financing round with investors including Droia Ventures, Frazier Life Sciences, Novo Holdings A/S and Lifearc Ventures.
Asthma affects about 300 million people worldwide. Inflammation in asthma may drive irreversible airway remodeling due to subepithelial fibrosis, extracellular matrix degradation and increased smooth muscle cell mass levels, among others. In vitro and in vivo assays were performed to test MutT homolog 1 (MTH1) as a therapeutic target in allergic airway inflammation.
The U.S. FDA rejected, for the second time, Elevar Therapeutics Inc.’s NDA of a novel combination therapy for advanced liver cancer, which comprised Jiangsu Hengrui Pharmaceutical Co. Ltd.’s PD-1 inhibitor camrelizumab and HLB Co. Ltd.’s small-molecule tyrosine kinase inhibitor, rivoceranib.
Ampersand Biomedicines Inc. has secured $65 million in series B funding from investors including Ampersand’s founder, Flagship Pioneering, to support advancement of two lead programs and a new discovery partnership in obesity.
RSS
